BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis
Blood · 2023
DOI: 10.1182/blood.2022019274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Anja Schmitt und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Ferroptosis, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, is characterized by an aggressive clinical course. In approximately one-third of patients with DLBCL, first-line multiagent immunochemotherapy fails to produce a durable response. Molecular heterogeneity and apoptosis resistance pose major therapeutic challenges in DLBCL treatment. To circumvent apoptosis resistance, the induction of ferroptosis might represent a promising strategy for lymphoma therapy. In this study, a compound library, targeting epigenetic modulators, was screened to identify ferroptosis-sensitizing drugs. Strikingly, bromodomain and extra-terminal domain (BET) inhibitors sensitized cells of the germinal center B-cell–like (GCB) subtype of DLBCL to ferroptosis induction and the combination of BET inhibitors with ferroptosis inducers, such as dimethyl fumarate or RSL3, synergized in the killing of DLBCL cells in vitro and in vivo. On the molecular level, the BET protein BRD4 was found to be an essential regulator of ferroptosis suppressor protein 1 expression and thus to protect GCB-DLBCL cells from ferroptosis. Collectively, we identified and characterized BRD4 as an important player in ferroptosis suppression in GCB-DLBCL and provide a rationale for the combination of BET inhibitors with ferroptosis-inducing agents as a novel therapeutic approach for DLBCL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
- Department of Molecular Medicine, Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany.
- Department of Biomedicine, University of Basel, Basel, Switzerland.
- Department for Internal Medicine, Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
- Institute of Molecular Tumor Biology, Faculty of Medicine, University of Münster, Münster, Germany.
- German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung) and German Cancer Research Center (Deutsches Krebsforschungszentrum), Heidelberg, Germany.
ORCID-Profile: Hannah Junge, Jan Labisch, Kerstin Menck, Claudia Lengerke, Mattia Zampieri, Pavel Klener, Alexandra Dolnikova
Zitieren
APA
Schmitt, A., Grimm, M., Kreienkamp, N., Junge, H., Labisch, J., Schuhknecht, L., Schönfeld, C., Görsch, E., Tibello, A., Menck, K., Bleckmann, A., Lengerke, C., Rosenbauer, F., Grau, M., Zampieri, M., Schulze-Osthoff, K., Klener, P., Dolnikova, A., Lenz, G., & Hailfinger, S. (2023). BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. https://doi.org/10.1182/blood.2022019274
Vancouver
Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023. doi:10.1182/blood.2022019274
BibTeX
@article{Schmitt2023,
author = {Schmitt, Anja and Grimm, Melanie and Kreienkamp, Nina and Junge, Hannah and Labisch, Jan and Schuhknecht, Laurentz and Schönfeld, Caroline and Görsch, Elsa and Tibello, Alessia and Menck, Kerstin and Bleckmann, Annalen and Lengerke, Claudia and Rosenbauer, Frank and Grau, Michael and Zampieri, Mattia and Schulze-Osthoff, Klaus and Klener, Pavel and Dolnikova, Alexandra and Lenz, Georg and Hailfinger, Stephan},
title = {BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019274}
}
EUVIMED